<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34826228</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1205-7541</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>100</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Canadian journal of physiology and pharmacology</Title>
          <ISOAbbreviation>Can J Physiol Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Citral inhibits the nociception in the rat formalin test: effect of metformin and blockers of opioid receptor and the NO-cGMP-K<sup>+</sup> channel pathway.</ArticleTitle>
        <Pagination>
          <StartPage>306</StartPage>
          <EndPage>313</EndPage>
          <MedlinePgn>306-313</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1139/cjpp-2021-0458</ELocationID>
        <Abstract>
          <AbstractText>The objective of the present study was to scrutinize the effect of nitric oxide (NO), cyclic GMP (cGMP), potassium channel blockers, and metformin on the citral-produced peripheral antinociception. The rat paw 1% formalin test was used to assess nociception and antinociception. Rats were treated with local peripheral administration of citral (10-100 µg/paw). The antinociception of citral (100 µg/paw) was evaluated with and without the local pretreatment of naloxone, NG-L-nitro-arginine methyl ester (L-NAME, a NO synthesis inhibitor), 1H-(1,2,4)-oxadiazolo(4,2-a)quinoxalin-1-one (ODQ, a soluble guanylyl cyclase inhibitor), metformin, opioid receptors antagonists, and K<sup>+</sup> channel blockers. Injection of citral in the rat paw significantly decreased the nociceptive effect of formalin administration during the two phases of the test. Local pretreatment of the paws with L-NAME and ODQ did not reduced the citral-induced antinociception. Glipizide or glibenclamide (K<sub>ir</sub>6.1-2; ATP-sensitive K<sup>+</sup> channel blockers), tetraethylammonium or 4-aminopyridine (K<sub>V</sub>; voltage-gated K<sup>+</sup> channel blockers), charybdotoxin (K<sub>Ca</sub>1.1; big conductance calcium-activated K<sup>+</sup> channel blocker), apamin (K<sub>Ca</sub>2.1-3; small conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel antagonist), or metformin, but not the opioid antagonists, reduced the antinociception of citral. Citral produced peripheral antinociception during both phases of the formalin test. These effects were due to the activation of K<sup>+</sup> channels and a biguanide-dependent mechanism.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ortiz</LastName>
            <ForeName>Mario I</ForeName>
            <Initials>MI</Initials>
            <AffiliationInfo>
              <Affiliation>Área Académica de Medicina del Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cariño-Cortés</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Área Académica de Medicina del Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muñoz-Pérez</LastName>
            <ForeName>Víctor M</ForeName>
            <Initials>VM</Initials>
            <AffiliationInfo>
              <Affiliation>Área Académica de Medicina del Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Medina-Solís</LastName>
            <ForeName>Carlo Eduardo</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>Área Académica de Odontología del Instituto de Ciencias de la Salud de la Universidad Autónoma del Estado de Hidalgo, San Agustín Tlaxiaca, Hidalgo, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castañeda-Hernández</LastName>
            <ForeName>Gilberto</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de México, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Canada</Country>
        <MedlineTA>Can J Physiol Pharmacol</MedlineTA>
        <NlmUniqueID>0372712</NlmUniqueID>
        <ISSNLinking>0008-4212</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000080462">Acyclic Monoterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011957">Receptors, Opioid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9100L32L2N</RegistryNumber>
          <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H2D2X058MU</RegistryNumber>
          <NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>T7EU0O9VPP</RegistryNumber>
          <NameOfSubstance UI="C007076">citral</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000080462" MajorTopicYN="N">Acyclic Monoterpenes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006152" MajorTopicYN="Y">Cyclic GMP</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059225" MajorTopicYN="N">Nociception</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011957" MajorTopicYN="N">Receptors, Opioid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">K+ channels</Keyword>
        <Keyword MajorTopicYN="N">antinociception</Keyword>
        <Keyword MajorTopicYN="N">canaux K+</Keyword>
        <Keyword MajorTopicYN="N">citral</Keyword>
        <Keyword MajorTopicYN="N">effet périphérique</Keyword>
        <Keyword MajorTopicYN="N">formalin test</Keyword>
        <Keyword MajorTopicYN="N">metformin</Keyword>
        <Keyword MajorTopicYN="N">metformine</Keyword>
        <Keyword MajorTopicYN="N">nociception</Keyword>
        <Keyword MajorTopicYN="N">peripheral effect</Keyword>
        <Keyword MajorTopicYN="N">rat</Keyword>
        <Keyword MajorTopicYN="N">test à la formaline</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>17</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34826228</ArticleId>
        <ArticleId IdType="doi">10.1139/cjpp-2021-0458</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
